Atossa Therapeutics(ATOS) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update • Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks • Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®) • Ended first quarter 2024 with $84.0 million of cash and cash equivalents and no debt SEATTLE, May 13, 2024— Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced financial results for the fiscal qu ...